59% Increase in total sleep time vs placebo (controlled study) 37 mo Normal sleep maintained after the last dose (chronic insomniacs) 1977 Year DSIP was first isolated 0 Documented dependence or withdrawal in clinical studies Studies show increased delta wave sleep Research on cortisol normalization Trials in chronic pain patients Demonstrated stress-reducing effects What to expect Your DSIP timeline
These medications excel at glycemic control and produce substantial weight loss through mechanisms centered on insulin secretion enhancement, glucagon suppression, and central appetite regulation via GLP-1 pathways
Scientific Insights and Studies Preliminary studies suggest that GHK-Cu may support skin regeneration by stimulating collagen production
Pentadeca Arginate has demonstrated potential in reversing opioid tolerance, allowing patients to achieve effective pain relief with lower doses of opioids
However, such a wide range of even opposite disturbances that can be all attenuated/counteracted, given a general counteracting potential, can match with the original cytoprotection concept perception holding the equal cell protection (necrosis prevention) against a variety of different agents (originally used absolute alcohol, boiling water, strong base, and strong acid claimed for common endogenous mechanisms)
